Matched sample baseline characteristics according to treatment of the first bleeding episode (bypassing agent vs FVIII or DDAVP and rFVIIa vs aPCC)
| Variable . | Bypassing agent, median (IQR) . | FVIII or DDAVP, median (IQR) . | P* . | rFVIIa,† median (IQR) . | aPCC, median (IQR) . | P* . |
|---|---|---|---|---|---|---|
| Patients, n | 60 | 60 | 57 | 57 | ||
| Age, y | 74.0 (24.0-91.0) | 72.5 (13.0-104.0) | .95 | 72.00 (39.00-91.00) | 77.00 (24.00-92.00) | .41 |
| Sex, n (%) | .69 | .41 | ||||
| Female | 25 (41.7) | 23 (38.3) | 37 (64.91) | 33 (57.89) | ||
| Male | 35 (58.3) | 37 (61.7) | 20 (35.09) | 24 (42.11) | ||
| Weight, kg | 70.0 (40.0-107.0) | 68.0 (40.0-113.0) | .49 | 70.00 (40.00-120.00) | 70.00 (44.00-107.00) | .66 |
| FVIII level, IU/dL | 2.0 (0.0-40.0) | 3.0 (0.0-34.0) | .61 | 1.25 (0.00-32.00) | 1.00 (0.00-40.00) | .41 |
| Hb, g/dL | 8.4 (3.0-14.2) | 8.8 (3.3-14.4) | .41 | 8.50 (3.00-14.00) | 8.40 (4.60-14.80) | .84 |
| Inhibitor titer, BU/mL | 9.3 (1.0-2765.0) | 8.0 (0.3-200.0) | .52 | 16.00 (1.00-2765.00) | 17.00 (0.10-1700.00) | .52 |
| Therapy delay, d | 0.01 (0.0-0.13) | 0.01 (0.0-0.11) | .46 | 0.01 (0.00-0.09) | 0.01 (0.00-0.54) | .64 |
| Cause of bleeding, n (%) | .51 | .62 | ||||
| Traumatic | 16 (26.7) | 13 (21.7) | 10 (17.54) | 8 (14.04) | ||
| Spontaneous | 44 (73.3) | 47 (78.3) | 47 (82.46) | 49 (85.96) | ||
| Bleeding site, n (%) | .99 | .55 | ||||
| Deep | 30 (50.0) | 30 (50.0) | 44 (77.19) | 44 (77.19) | ||
| Hemarthrosis | 3 (5.0) | 2 (3.3) | 0 (0.00) | 1 (1.75) | ||
| Mucosa | 15 (25.0) | 16 (26.7) | 5 (8.77) | 4 (7.02) | ||
| Skin | 12 (20.0) | 12 (20.0) | 8 (14.04) | 8 (14.04) | ||
| Severity of bleeding, n (%) | .63 | .56 | ||||
| Severe | 47 (78.3) | 49 (81.7) | 49 (85.96) | 51 (89.47) | ||
| Nonsevere | 13 (21.6) | 11 (18.3) | 8 (14.04) | 6 (10.53) | ||
| Variable . | Bypassing agent, median (IQR) . | FVIII or DDAVP, median (IQR) . | P* . | rFVIIa,† median (IQR) . | aPCC, median (IQR) . | P* . |
|---|---|---|---|---|---|---|
| Patients, n | 60 | 60 | 57 | 57 | ||
| Age, y | 74.0 (24.0-91.0) | 72.5 (13.0-104.0) | .95 | 72.00 (39.00-91.00) | 77.00 (24.00-92.00) | .41 |
| Sex, n (%) | .69 | .41 | ||||
| Female | 25 (41.7) | 23 (38.3) | 37 (64.91) | 33 (57.89) | ||
| Male | 35 (58.3) | 37 (61.7) | 20 (35.09) | 24 (42.11) | ||
| Weight, kg | 70.0 (40.0-107.0) | 68.0 (40.0-113.0) | .49 | 70.00 (40.00-120.00) | 70.00 (44.00-107.00) | .66 |
| FVIII level, IU/dL | 2.0 (0.0-40.0) | 3.0 (0.0-34.0) | .61 | 1.25 (0.00-32.00) | 1.00 (0.00-40.00) | .41 |
| Hb, g/dL | 8.4 (3.0-14.2) | 8.8 (3.3-14.4) | .41 | 8.50 (3.00-14.00) | 8.40 (4.60-14.80) | .84 |
| Inhibitor titer, BU/mL | 9.3 (1.0-2765.0) | 8.0 (0.3-200.0) | .52 | 16.00 (1.00-2765.00) | 17.00 (0.10-1700.00) | .52 |
| Therapy delay, d | 0.01 (0.0-0.13) | 0.01 (0.0-0.11) | .46 | 0.01 (0.00-0.09) | 0.01 (0.00-0.54) | .64 |
| Cause of bleeding, n (%) | .51 | .62 | ||||
| Traumatic | 16 (26.7) | 13 (21.7) | 10 (17.54) | 8 (14.04) | ||
| Spontaneous | 44 (73.3) | 47 (78.3) | 47 (82.46) | 49 (85.96) | ||
| Bleeding site, n (%) | .99 | .55 | ||||
| Deep | 30 (50.0) | 30 (50.0) | 44 (77.19) | 44 (77.19) | ||
| Hemarthrosis | 3 (5.0) | 2 (3.3) | 0 (0.00) | 1 (1.75) | ||
| Mucosa | 15 (25.0) | 16 (26.7) | 5 (8.77) | 4 (7.02) | ||
| Skin | 12 (20.0) | 12 (20.0) | 8 (14.04) | 8 (14.04) | ||
| Severity of bleeding, n (%) | .63 | .56 | ||||
| Severe | 47 (78.3) | 49 (81.7) | 49 (85.96) | 51 (89.47) | ||
| Nonsevere | 13 (21.6) | 11 (18.3) | 8 (14.04) | 6 (10.53) | ||